News from Bayer
May 19, 2022
Not intended for U.S. and UK Media
Bayer to present key data across oncology portfolio showcasing significant advances in cancer care at 2022 ASCO Annual Meeting
May 19, 2022
Not intended for U.S. and UK Media
Verquvo™ (vericiguat) approved in China to treat patients with chronic heart failure and reduced ejection fraction
May 17, 2022
Not intended for U.S. and UK Media – 59th ERA Congress Paris & Virtual 2022:
Bayer to present new Kerendia™ (finerenone) data from comprehensive clinical trial program in chronic kidney disease and type 2 diabetes
Explore All Stories